Asarina Pharma

About Us

Asarina Pharma Asarina Pharma is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Our product pipeline is built on over 40 years of research, and with our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions from Tourette syndrome to OCD..

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Asarina Pharma over-allotment option fully exercised as stabilization period of share offering ends

Wed, Oct 24, 2018 08:00 CET

Stockholm - October 24, 2018: Erik Penser Bank (“EPB”) has been the stabilization manager for Asarina Pharma AB (publ) in connection with its recent offering of 6,800,000 new shares ("the Offer"), and the listing of the Company’s shares on Nasdaq First North. EPB hereby announces the stabilization period of thirty calendar days following the listing of the Company's shares ended 23 October, with no stabilization transactions having been carried out.In its capacity as stabilization manager, EPB had the authority to carry out transactions aimed at supporting the price of the Asarina share at

Asarina Pharma: sharp rise on first day of trading on Nasdaq First North

Mon, Sep 24, 2018 20:49 CET

After 40 years’ of research developing its breakthrough PMDD treatment Sepranolone, Asarina Pharma hit the ground running on Monday 24 September as it launched on Nasdaq First North in Stockholm. With major institutions getting behind the research—how did the successful market launch feel for the scientific and business team at Asarina Pharma?WHAT DOES TODAY MEAN TO YOU? CEO, Peter Nordkild: “We’ve come a long way–yet in many ways this is just another beginning. Now it’s time to deliver. A successful flotation increases our responsibility to deliver the results from our Phase IIB study

Nasdaq Stockholm Welcomes Asarina Pharma to First North

Mon, Sep 24, 2018 10:44 CET

Stockholm, September 24, 2018— Nasdaq (Nasdaq: NDAQ) today announced that trading in Asarina Pharma AB’s shares (short name: ASAP) commences today on Nasdaq First North in Stockholm. Read Nasdaq First North's Press Release below, or HERE. Stockholm, September 24, 2018— Nasdaq (Nasdaq: NDAQ) announces that the trading in Asarina Pharma AB’s shares (short name: ASAP) will commence today on Nasdaq First North in Stockholm. Asarina Pharma belongs to the health care

Asarina Pharma IPO oversubscribed 175%: CEO welcomes new shareholders

Thu, Sep 20, 2018 14:48 CET

With its IPO listing oversubscribed by 175%, Asarina Pharma is firmly in the investor and scientific spotlight. Here, CEO Peter Nordkild shares upcoming research and business highlights with the company’s new shareholders."The major commitments we received from large institutional investors in North America, Europe and Sweden reflect a historic shift in attitudes towards women’s health,” says Asarina Pharma CEO Peter Nordkild. “With a strong hereditary element PMDD has gone untreated and undiagnosed for generations. Our business strategy, combined with the pedigree of our research, means a

Asarina Pharma AB (publ) has received approval for listing of the company’s shares on Nasdaq First North

Wed, Sep 19, 2018 12:27 CET

Nasdaq has approved Asarina Pharma AB (publ) (”Asarina Pharma” or the “Company”) for listing on Nasdaq First North. First day of trading in the Company’s shares is on Monday, 24 September, 2018.Asarina Pharma has recently completed a share issue for listing on Nasdaq First North. The share issue raised SEK 142.8M before issue costs. Provided that the over-allotment option of up to 350,000 shares is fully exercised, the Company will receive a total of SEK 150.2M before issue costs. Following the share issue, Asarina Pharma will have around 1,200 shareholders. Nasdaq’s review of Asarina

Share issue in Asarina Pharma AB (publ) oversubscribed before listing on First North

Mon, Sep 17, 2018 16:40 CET

On 24 August 2018, the Board of Directors of Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”), resolved, with the authorization from the Extraordinary General Meeting on 28 June, 2018, on a share issue of up to 6,800,000 shares (the “Offer”) and to apply for admission to trading of the Company’s share on Nasdaq First North. First day of trading is scheduled for September 24, 2018. The interest in participating in the Offer has been strong and the Offer was subscribed to approximately 275 percent. The Offer will provide the Company with SEK 142.8M before issue costs. Conditioned

There are no items matching the current filter

There are no more items matching the current filter

Share